Study of Matrix Metalloproteinase -1 Polymorphism and Susceptibility to Bladder Cancer

Nikfarjam, Delaram; Tafvizi, farzaneh; Salehipoure , Masoud

Volume 25, Issue 9 (Nov 2017) JSSU 2017, 25(9): 708-718 | Back to browse issues page

Mendeley

Zotero

RefWorks

Nikfarjam D, Tafvizi F, Salehipoure M. Study of Matrix Metalloproteinase -1 Polymorphism and Susceptibility to Bladder Cancer . JSSU 2017; 25 (9) :708-718
URL: http://jssu.ssu.ac.ir/article-1-4174-en.html

Study of Matrix Metalloproteinase -1 Polymorphism and Susceptibility to Bladder Cancer

Delaram Nikfarjam

, Farzaneh Tafvizi ^*

, Masoud Salehipoure

Abstract: (5251 Views)

Introduction: Matrix metalloproteinase-1 with the destruction of the basement membrane and extracellular matrix not only facilitates the spread of cancer cells, but also with the release of growth factors and angiogenesis plays a key role in cancer cell survival and nutrition. The purpose of this study was to recognize the relation between the polymorphism of Matrix metalloproteinase-1 gene and risk of bladder cancer.
Methods: This case-control study included 157 patients with bladder cancer and 143 healthy controls who were
age-matched. First, DNA extraction from peripheral blood and then PCR was performed using specific primers. Then, RFLP method was used to evaluate the MMP-1 (-1607) polymorphism.
Results: There was no significant difference between the frequency of 1G/1G, 2G/2G allels (P˃0.05). There was no association between polymorphism and susceptibility to bladder cancer [OR:1.23, 95%CI
(0.67-2.28),P=0.49].
Conclusion: Due to the lack of association between MMP-1 polymorphism (-1607) and the risk of bladder- cancer, it is suggested that other polymorphisms of the matrix metalloproteinase-1 gene will be investigated

Keywords: Bladder cancer, Matrix Metalloproteinases, Polymorphism

Full-Text [PDF 979 kb] (1364 Downloads)

Type of Study: Original article | Subject: Genetics
Received: 2017/04/22 | Accepted: 2017/07/29 | Published: 2017/12/11

References

1. Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International Variations in Bladder Cancer Incidence and Mortality. Eur Urol 2014; 66(1): 59-73.

2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27(3): 289-93.

3. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63(2): 234-41.

4. Van Schaik RHN, Van der Heiden IP, Van den Anker JN, Lindemans J. CYP3A5 Variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48(10): 1668-71.

5. Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young pationts. J Urol 1998; 159(5): 1493-96.

6. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207-14.

7. Sun Y, Sun Y, Wenger L, Rutter J L, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem 1999; 274(17): 11535-40.

8. Nagase H, Woessner JF. Matrix metalloproteinases. J Biological Chemistry 1999; 274(31): 21491-21494.

9. Brinckerhoff CE, Rutter JL, Benbow U. Interstial collagenase as marker of tumor progression. Clin Cancer Res 2000; 6: 4823-30.

10. Folgueras AR, Pendas AM, Sanches LM, Lopez C. Matrix metalloproteinases in cancer:from new function to improved inhibition strategies. Int J Dev Biol 2004; 48(5-6): 411-424.

11. Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 2005; 106(6): 127-132.

12. Rundhaug JE. Matrix metalloproteinase and angiogenesis. J Cell Mol Med 2005; 9(2): 267-285.

13. Visse F, Nagase H, Murphy G. Structure and function of MMPS and TIMPS. Circulation Res 2006; 69(3): 562-573.

14. Chamberlain SH, Hemmer RM, Brinckerhoff CE. Novel phorbol ester response region in collagenase promoter binds Fos and Jun. J Cell Biochem 1993; 52: 337-51.

15. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella J F,Ozelius L J, et al. A single nucleotide polymorphism in the matrix metalloprpteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321-5.

16. Tower G B, Conn CI, Belguise K, Dany C, Brinkerhoff CE. Fra-1 targets the AP-1 site/2G single nucleotide polymorphism(ETS site)in the MMP-1 promoter. Eur Biochem 2003; 270(20): 4216-4225.

17. Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, et al. Investigation of cutaneous malignant melanoma is influenced by matrix metalloprpteinase-1 gene polymorphism. Cancer Res 2001; 61(4): 1296-98.

18. Simforoosh N, Nouralizadeh A. 2006.Iranian textbook of urology.2.Teimoorzadeh.Bladder Cancer, 873-893.

19. Kader AK, Liu J, Shao L, Dinney C, Lin J, Wang Y, et al. Matrix metalloproteinase polymorphisms are associated with Bladder Cancer Invasiveness. clin cancer Res 2007; 2614-262.

20. Motavali Bashi M, Kouhkan F, Hijati Z. The role of snp in Fibroblast collagenase gene with increasing of metastasis risk and viability reduction in Breast cancer patients. J molecular and cellular researches (Iranian Journal of Biology) 2013; 26(3): 365-377. [Persian]

21. Wyatt C, Charles I, Coon J, Gibson J, Brinckerhoff E. Potential for 2G single nucleotide polymorphism in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res 2002; 62(24): 7200-2.

22. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovase Res 2006; 69(3): 636-45.

23. Cao Z, Li C, Jin L, Corbet EF. Association of Matrix metalloproteinase-1 promoter polymorphism with generalized aggressive periodontitis in a chines population. J Periodonal Res 2005; 40: 427-431.

24. Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda YA. Single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer 2003; 106(3): 372-374.

25. Six L, Crimm C, Leodolter S, Tempfer C, Zeilinger R, Sliutz G, et al. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of pationts with ovarian cancer. Gynecol Oncol 2006; 100(3): 506-510.

26. Zinzindohoue F, Lecomte T, Ferraz JM, Laurent-Puig P. Prognostic significant of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005; 11(2-1): 594-599.

27. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001; 61(21): 7825-9.

28. O-charoenrat P, Leksrisakul P, Sangruchi S. A Functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressivenss of head and neck cancer. Int J Cancer 2006; 118(10): 2548-53.

29. Tao L, Li Z, Lin L, Lei Y, Hongyuan Y, Hongwei J, et al. MMP-1،2،3،7،and 9 Gene polymorphisms and Urinary Cancer Risk: A Meta-Analysis. Genet Test Mol Biomarkers 2015; 19(10): 548-555.

30. wieczore KE, Reszka E, Jablonowski Z, Jablonska E, Krol MB, Grzegorczyk A, et al. Genetic Polymorphisms in matrix metalloproteinases(MMPS)and tissue inhibitors of MMPS (TIMPS) and bladder cancer susceptibility. BJU Int 2013; 112(8): 1207-14.

31. Yan Y, Liang H, Li T, Li M, Li R, Qin X, et al. The MMP1, MMP2 and MMP9 gene polymorphisms and susceptibility to bladder Cancer: a meta-analysis . Tumor Biol 2014; 35: 3047-3052.

32. Srivastava P, Gangwar R, Kapoor R, Mittal R. Bladder Cancer Risk Associated with Genotypic polymorphism of the matrix Metalloproteinas-1 and 7 in North Indian Population. Hindawi 2010; 29: 37-46.

33. Tasci AL, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU International 2008:101(4); 503-7.